%0 Journal Article %A Benjamin Steinegger %A Clara Granell %A Giacomo Rapisardi %A Sergio Gómez %A Joan T. Matamalas %A David Soriano-Paños %A Jesús Gómez-Gardeñes %A Alex Arenas %T Retrospective study of the first wave of COVID-19 in Spain: analysis of counterfactual scenarios %D 2021 %R 10.1101/2021.02.16.21251832 %J medRxiv %P 2021.02.16.21251832 %X One of the most important questions on the COVID-19 pandemic is ascertaining the correct timing to introduce non-pharmaceutical interventions (NPIs), based mainly on mobility restrictions, to control the rising of the daily incidence in a specific territory. Here, we make a retrospective analysis of the first wave of the epidemic in Spain and provide a set of useful insights to optimize actions in the near future. We have reconstructed the exposure times, from infection to detectability, to correctly estimate the reproduction number Rt. This enables us to analyze counterfactual scenarios to understand the impact of earlier or later responses, decoupling containment measures from natural immunity. Our results quantify the differences in the number of fatalities for earlier and later responses to the epidemic in Spain.Teaser “We propose a backward analysis of pandemic incidence in a region to determine the correct timing of authorities’ non-pharmaceutical interventions to fight COVID-19”Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding: A.A., B.S., and S.G. acknowledge financial support from Spanish MINECO (Grant No. PGC2018-094754-B-C21), Generalitat de Catalunya (Grant No. 2017SGR-896), and Universitat Rovira i Virgili (Grant No. 2019PFR-URV-B2-41). A.A. also acknowledges support from Generalitat de Catalunya (PDAD14/20/00001), ICREA Academia, and the James S. McDonnell Foundation (Grant No. 220020325). J. G.-G. and D. S.-P. acknowledge financial support from MINECO and FEDER funds (Project No. FIS2017-87519-P) and from the Departamento de Industria e Innovacion del Gobierno de Aragon y Fondo Social Europeo (FENOL group E-19). C.G. acknowledges financial support from Beatriz de Galindo (Ministerio de Ciencia, Innovacion y Universidades). B.S. acknowledges financial support from the European Union Horizon 2020 research and innovation program under the Marie Skłodowska-Curie Grant Agreement No. 713679 and from the Universitat Rovira i Virgili (URV).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:I confirm that we have followed all relevant ethical guidelines on this manuscript.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesOnly public data was used. %U https://www.medrxiv.org/content/medrxiv/early/2021/02/18/2021.02.16.21251832.full.pdf